|
1
|
Ostrom QT, Cioffi G, Waite K, Kruchko C
and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain
and other central nervous system tumors diagnosed in the United
States in 2014–2018. Neuro Oncol. 23:iii1–iii105. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nicholson JG and Fine HA: Diffuse glioma
heterogeneity and its therapeutic implications. Cancer Discov.
11:575–590. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zeng J, Li X, Sander M, Zhang H, Yan G and
Lin Y: Oncolytic Viro-Immunotherapy: An emerging option in the
treatment of gliomas. Front Immunol. 12:7218302021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stupp R, Taillibert S, Kanner A, Read W,
Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K,
et al: Effect of tumor-treating fields plus maintenance
temozolomide vs maintenance temozolomide alone on survival in
patients with glioblastoma: A randomized clinical trial. JAMA.
318:2306–2316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brown CE, Hibbard JC, Alizadeh D,
Blanchard MS, Natri HM, Wang D, Ostberg JR, Aguilar B, Wagner JR,
Paul JA, et al: Locoregional delivery of IL-13Rα2-targeting CAR-T
cells in recurrent high-grade glioma: A phase 1 trial. Nat Med.
30:1001–1012. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ostrom QT, Cioffi G, Waite K, Kruchko C
and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain
and other central nervous system tumors diagnosed in the United
States in 2014–2018. Neuro Oncol. 23:iii1–iii105. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rees JH: Diagnosis and treatment in
neuro-oncology: An oncological perspective. Br J Radiol. 84(Spec No
2): S82–S89. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huse JT and Holland EC: Targeting brain
cancer: Advances in the molecular pathology of malignant glioma and
medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weller M, Stupp R, Reifenberger G, Brandes
AA, van den Bent MJ, Wick W and Hegi ME: MGMT promoter methylation
in malignant gliomas: Ready for personalized medicine? Nat Rev
Neurol. 6:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ellingson BM, Wen PY and Cloughesy TF:
Modified criteria for radiographic response assessment in
glioblastoma clinical trials. Neurotherapeutics. 14:307–320. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kanehira M, Harada Y, Takata R, Shuin T,
Miki T, Fujioka T, Nakamura Y and Katagiri T: Involvement of
upregulation of DEPDC1 (DEP domain containing 1) in bladder
carcinogenesis. Oncogene. 26:6448–6455. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Y, Tian Y, Zhong W, Wang N, Wang Y,
Zhang Y, Zhang Z, Li J, Ma F, Zhao Z and Peng Y: Artemisia argyi
essential oil inhibits hepatocellular carcinoma metastasis via
suppression of DEPDC1 dependent Wnt/β-catenin signaling pathway.
Front Cell Dev Biol. 9:6647912021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang W, Li A, Han X, Wang Q, Guo J, Wu Y,
Wang C and Huang G: DEPDC1 up-regulates RAS expression to inhibit
autophagy in lung adenocarcinoma cells. J Cell Mol Med.
24:13303–13313. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Q, Jiang S, Liu J, Ma G, Zheng J and
Zhang Y: DEP domain containing 1 promotes proliferation, invasion,
and epithelial-mesenchymal transition in colorectal cancer by
enhancing expression of suppressor of zest 12. Cancer Biother
Radiopharm. 36:36–44. 2021.PubMed/NCBI
|
|
17
|
Zhang L, Du Y, Xu S, Jiang Y, Yuan C, Zhou
L, Ma X, Bai Y, Lu J and Ma J: DEPDC1, negatively regulated by
miR-26b, facilitates cell proliferation via the up-regulation of
FOXM1 expression in TNBC. Cancer Lett. 442:242–251. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen L, Li H, Liu R, Zhou C, Bretches M,
Gong X, Lu L, Zhang Y, Zhao K, Ning B, et al: DEPDC1 as a crucial
factor in the progression of human osteosarcoma. Cancer Med.
12:5798–5808. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang L, Chen K, Cai ZP, Chen FC, Shen HY,
Zhao WH, Yang SJ, Chen XB, Tang GX and Lin X: DEPDC1 promotes cell
proliferation and tumor growth via activation of E2F signaling in
prostate cancer. Biochem Biophys Res Commun. 490:707–712. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Y, Jiang Y, Jiang M, Zhang J, Yang B,
She Y, Wang W, Deng Y and Ye Y: Protocadherin 10 inhibits cell
proliferation and induces apoptosis via regulation of DEP domain
containing 1 in endometrial endometrioid carcinoma. Exp Mol Pathol.
100:344–352. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mi Y, Zhang C, Bu Y, Zhang Y, He L, Li H,
Zhu H, Li Y, Lei Y and Zhu J: DEPDC1 is a novel cell cycle related
gene that regulates mitotic progression. BMB Rep. 48:413–418. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sendoel A, Maida S, Zheng X, Teo Y,
Stergiou L, Rossi CA, Subasic D, Pinto SM, Kinchen JM, Shi M, et
al: DEPDC1/LET-99 participates in an evolutionarily conserved
pathway for anti-tubulin drug-induced apoptosis. Nat Cell Biol.
16:812–820. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao Z, Zhang KN, Wang Q, Li G, Zeng F,
Zhang Y, Wu F, Chai R, Wang Z, Zhang C, et al: Chinese glioma
genome atlas (CGGA): A comprehensive resource with functional
genomic data from chinese glioma patients. Genomics Proteomics
Bioinformatics. 19:1–12. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang K, Liu X, Li G, Chang X, Li S, Chen
J, Zhao Z, Wang J, Jiang T and Chai R: Clinical management and
survival outcomes of patients with different molecular subtypes of
diffuse gliomas in China (2011–2017): A multicenter retrospective
study from CGGA. Cancer Biol Med. 19:1460–1476. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chakrabarty S, LaMontagne P, Shimony J,
Marcus DS and Sotiras A: MRI-based classification of IDH mutation
and 1p/19q codeletion status of gliomas using a 2.5D hybrid
multi-task convolutional neural network. Neurooncol Adv.
5:vdad0232023.PubMed/NCBI
|
|
27
|
Wesseling P, van den Bent M and Perry A:
Oligodendroglioma: Pathology, molecular mechanisms and markers.
Acta Neuropathol. 129:809–827. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amisaki M, Yagyu T, Uchinaka EI, Morimoto
M, Hanaki T, Watanabe J, Tokuyasu N, Sakamoto T, Honjo S and
Fujiwara Y: Prognostic value of DEPDC1 expression in tumor and
non-tumor tissue of patients with hepatocellular carcinoma.
Anticancer Res. 39:4423–4430. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yuan SG, Liao WJ, Yang JJ, Huang GJ and
Huang ZQ: DEP domain containing 1 is a novel diagnostic marker and
prognostic predictor for hepatocellular carcinoma. Asian Pac J
Cancer Prev. 15:10917–10922. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bin X, Luo Z, Wang J and Zhou S:
Identification of a five immune term signature for prognosis and
therapy options (Immunotherapy versus Targeted Therapy) for
patients with hepatocellular carcinoma. Comput Math Methods Med.
2023:89589622023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, Li Y, Dai Y, Wang D, Wang X, Cao
Y, Liu W and Tao Z: Glycolysis-related gene expression profiling
serves as a novel prognosis risk predictor for human hepatocellular
carcinoma. Sci Rep. 11:188752021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shao F, Ling L, Li C, Huang X, Ye Y, Zhang
M, Huang K, Pan J, Chen J and Wang Y: Establishing a
metastasis-related diagnosis and prognosis model for lung
adenocarcinoma through CRISPR library and TCGA database. J Cancer
Res Clin Oncol. 149:885–899. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu Y, Sun L, Yu J, Xiang Y, Shen M, Wasan
HS, Ruan S and Qiu S: Identification of biomarkers in colon cancer
based on bioinformatic analysis. Transl Cancer Res. 9:4879–4895.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shen X and Han J: Overexpression of gene
DEP domain containing 1 and its clinical prognostic significance in
colorectal cancer. J Clin Lab Anal. 34:e236342020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim J: In silico analysis of
differentially expressed genesets in metastatic breast cancer
identifies potential prognostic biomarkers. World J Surg Oncol.
19:1882021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang M, Zhang H, Gao S and Huang W: DEPDC1
and KIF4A synergistically inhibit the malignant biological behavior
of osteosarcoma cells through Hippo signaling pathway. J Orthop
Surg Res. 18:1452023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jia B, Liu J, Hu X, Xia L and Han Y:
Pan-cancer analysis of DEPDC1 as a candidate prognostic biomarker
and associated with immune infiltration. Ann Transl Med.
10:13552022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Harada Y, Kanehira M, Fujisawa Y, Takata
R, Shuin T, Miki T, Fujioka T, Nakamura Y and Katagiri T:
Cell-permeable peptide DEPDC1-ZNF224 interferes with
transcriptional repression and oncogenicity in bladder cancer
cells. Cancer Res. 70:5829–5839. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou C, Wang P, Tu M, Huang Y, Xiong F and
Wu Y: DEPDC1 promotes cell proliferation and suppresses sensitivity
to chemotherapy in human hepatocellular carcinoma. Biosci Rep.
39:BSR201909462019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Feng X, Zhang C, Zhu L, Zhang L, Li H, He
L, Mi Y, Wang Y, Zhu J and Bu Y: DEPDC1 is required for cell cycle
progression and motility in nasopharyngeal carcinoma. Oncotarget.
8:63605–63619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Obara W, Ohsawa R, Kanehira M, Takata R,
Tsunoda T, Yoshida K, Takeda K, Katagiri T, Nakamura Y and Fujioka
T: Cancer peptide vaccine therapy developed from oncoantigens
identified through genome-wide expression profile analysis for
bladder cancer. Jpn J Clin Oncol. 42:591–600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo W, Li H, Liu H, Ma X, Yang S and Wang
Z: DEPDC1 drives hepatocellular carcinoma cell proliferation,
invasion and angiogenesis by regulating the CCL20/CCR6 signaling
pathway. Oncol Rep. 42:1075–1089. 2019.PubMed/NCBI
|
|
43
|
Alorjani M, Aburub M, Al-Trad B, Hamad MA,
AbuAlarja M, Bashir SA, Al-Batayneh K and Zoubi MA: The prevalence
of CHEK1 and CHEK2 mutations in prostate cancer: A retrospective
cohort Study. Med Arch. 77:8–12. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen Y, Zhang S, Li Z, Yin B, Liu Y and
Zhang L: Discovery of a dual-target inhibitor of CDK7 and HDAC1
that induces apoptosis and inhibits migration in colorectal cancer.
ChemMedChem. 18:e2023002812023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Landsburg DJ, Morrissette JJ, Nasta SD,
Barta SK, Schuster SJ, Svoboda J, Chong EA and Bagg A: TP53
mutations predict for poor outcomes in patients with newly
diagnosed aggressive B-cell lymphomas in the current era. Blood
Adv. 7:7243–7253. 2023. View Article : Google Scholar : PubMed/NCBI
|
